Brief: Moberg Pharma And Taisho Sign Exclusive License Agreement For Mob-015 In Japan
Sept 30 (Reuters) - Moberg Pharma AB (publ) MBPH.ST :
* MOBERG PHARMA AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT
FOR
MOB-015 IN JAPAN
* MOBERG PHARMA- ELIGIBLE TO RECEIVE MILESTONES OF UP TO $50
MILLION CONTINGENT ON DEVELOPMENT & COMMERCIAL SUCCESS, AS WELL
AS SUPPLY FEES INCLUDING ROYALTIES.
* MOBERG PHARMA AB - MAJORITY OF MILESTONE PAYMENTS ARE
CONTINGENT
ON SALES TARGETS, WITH BALANCE CONTINGENT ON DEVELOPMENT AND
REGULATORY MILESTONES.
Source text for Eikon: ID:nWkr6psJ57
Further company coverage: MBPH.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10